Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion
作者:Ting‐Shi Su, Liqing Li, Liqing Li, Wan-Wan Meng, Yudan Wang, Yitian Chen, Jian-Xu Li, Youqin Du, Song Qu, Chang Zhao, De‐Jia Huang, Shi‐Xiong Liang, Le‐Qun Li, Le‐Qun Li · 发表于:Frontiers in Oncology · 年份:2020 · DOI:10.3389/fonc.2020.01205 · 被引用次数:16 · 研究领域:Hepatocellular Carcinoma Treatment and Prognosis、Cancer Mechanisms and Therapy、Cholangiocarcinoma and Gallbladder Cancer Studies
Background: Major vessel invasion (MVI) is a terminal manifestation of hepatocellular carcinoma (HCC), carries an extremely poor prognosis. In Chinese and Korean HCC guidelines, transarterial chemoembolization (TACE) or/and radiotherapy (RT) is adopted for treatment of MVI. In current study, we aimed to compare the long-term outcome of TACE+RT to RT alone in patients with local advanced HCC with MVI. Methods: In this retrospective study, 148 treatment-naive patients of HCC with MVI were enrolled. Of the patients enrolled, 49 received TACE+RT treatment, while 99 patients received RT alone as a monotherapy. Overall survival (OS), progression-free survival (PFS), and intrahepatic control were evaluated using univariable and propensity-score matched analyses. Results: During follow-up, 126 (85.1%) patients died. The median follow-up time was 55.0 months in RT group and 57.0 months in TACE+RT group. TACE+RT group showed better OS and PFS than the RT group, but intrahepatic control was comparable in these two groups. Of 41 cases well-pairs after propensity score matching, the associations between TACE+RT and better OS and PFS remained (15.0 versus 8.0 months, and 8.0 versus 4.0 months, all P<0.05). The 1-, 2-, 3-, and 5-year OS in the TACE+RT group were 56.1%%, 28.6%, 20.8%, and 15.7% versus 31.5%, 13.1%, 9.8%, and 6.7% in the RT group, respectively (P=0.017). The 6-, 12-, 24-month rates in the TACE+RT group were 51.2%, 39.0%, and 23.1% versus 36.6%, 13.9%, and 11.1% in the RT grou...